hMLH1 rs1799977 polymorphism may contribute to the etiology of early-onset lung cancer as well as some specific subtype of lung cancer.

Microsatellite instability and loss of MLH1 expression was rare, suggesting that MLH1 promoter methylation does not usually lead to gene silencing in lung cancer.

This is the first case-control study to show a significant association between the hMLH1-93G-->A polymorphism and the susceptibility to and prognosis of lung cancer.

genetic polymorphism is associated with the risk of lung cancer among never smokers

High allelic loss of MLH1 correlates with non-small cell lung cancer diagnosis.

UDownregulation of MLH1 is associated with non-small cell lung cancer.

cisplatin-based adjuvant chemotherapy is more beneficial for non-small cell lung cancer patients without hMLH1 methylation. hMLH1 methylation may have a potential to become a biomarker of individualized therapy for NSCLC patients.

miR-148b mimic sensitized A549 xenografts to irradiation in vivo Our study demonstrated that miR-148b regulates radioresistance of lung cancer cells by modulating MLH1 expression level. miR-148b may represent a new therapeutic target for the intervention of lung cancer.

hMLH1 (rs1800734) AA genotype is associated with increased risk of lung cancer development.

MLH1 methylation is a frequent molecular event in colorectal cancer and lung cancer patients

This study demonstrated that Aberrant methylation of mutL homolog 1 is associated with increased risk of non-small cell lung cancer

Human mutL homolog 1 (MLH1) is a member of the MMRs, and its mutation is found in Lynch syndrome (LS). In addition to the high incidence of colorectal cancer, LS patients often have other primary cancers. A new mutL homolog 1 c.1896+5G>A germline mutation detected in a Lynch syndrome-associated lung and gastric double primary cancer patient.

DNMT1 promotes cell proliferation via methylating hMLH1 and hMSH2 promoters in EGFR-mutated non-small cell lung cancer.